Gelonghui, April 9 | According to the Zhejiang Securities Research Report, Fosun Pharmaceutical (600196.SH)'s revenue in 2023 increased by about 12.43% year on year. Among them, revenue from key varieties such as Hans form, injectable trastuzumab, and Sukexin maintained rapid growth. I am optimistic that the company will become one of the few domestic pharmaceutical companies with the ability to commercialize innovative drugs internationally, and I am also optimistic about the company's international implementation. The company's profit forecast for 2023-2025 was lowered considering the impact of the company's 2023 COVID-related products and asset impairment, and the drag on financial expenses due to US dollar interest rate hikes, etc., which exceeded our previous expectations. At the same time, considering the base of the company's three major business segments and the continuity of business growth, the 2024-2025 revenue was also slightly lowered. Maintain a “buy” rating.